CTOs on the Move

Resilience Technology Corporation

www.resilience.com

 
Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Robert Brown
Senior Director of Cyber Resilience Profile
Michael Good
Director Security Operations Profile
Brandy Duso
Director of Compliance and Risk Profile
Bill Reid
CISO and VP, Security and Privacy Profile
Chris Taylor
Senior Director Information Technology Profile

Funding

Resilience Technology Corporation raised $750M on 11/23/2020
Resilience Technology Corporation raised $625M on 06/06/2022

Similar Companies

Onconome

Onconome is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Martek Biosciences Corporation

Martek Biosciences Corporation is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Century Hospice

New Century Hospice is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Orion Genomics

Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inflammatix

Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.